

Supplemental Table 1. Antibodies used for cell or tissue staining.

| Antibody/reagent | Clone | Application (Conc. µg/ml) | Supplier (catalog number) |
|---|-------------------|--------------------------------------|--|
| CD31 | 390 | FC (4.0) | Thermofisher (A14715) |
| CD45 | 30-F11 REA737 | FC (3.0) TS (3.0) | Miltenyi (130-105-463) Miltenyi (130-110-795) |
| MEFSK4 | MEFSK4 | FC (1.5) | Miltenyi Biotec (130-102-302, 130-102-352) |
| Sca-1 | REA422 | FC (3.0) | Miltenyi Biotec (130-106-427) |
| CD44 | REA664 | FC (3.0) | Miltenyi Biotec (130-110-117) |
| CD166 | REA370 | FC (3.0) | Miltenyi Biotec (130-105-487) |
| CD146 | ME-9F1 | FC (3.0) | Miltenyi Biotec (130-102-846) |
| αSMA | 1A4 | FC (4.0) TS (2.0) TS (2.5) | eBioscience (41-9760-80) eBioscience (53-9760-80) |
| Wheat germ agglutinin | NA | TS (5.0) | Vector Labs (B-1025) |
| Isolectin B4 | NA | TS (5.0) | Vector Labs (B-1205) |
| NG2 | Rabbit polyclonal | TS (1:100) | Dr. William Stallcup |
| Vimentin | NA | TS (9.0) | Abcam (ab45939) |
| DDR2 | N-20 | TS (2.0) | Santa Cruz (sc7555) |
| DsRed | Rabbit polyclonal | TS (1:100) | Clontech (632496) |
| FC: flow cytometry; TS: tissue staining | | | |

Supplemental Table 2. Time point comparison for percent of proliferating fibroblasts after transverse aortic constriction.

| | | Days of transverse aortic constriction (lesion) | | | |
|---|----|---|-----|----|----|
| | | 5 | 7 | 14 | 21 |
| Days of transverse aortic constriction (lesion) | 7 | ns | | | |
| | 14 | * | *** | | |
| | 21 | *** | *** | ns | |
| | 42 | ** | *** | ns | ns |

P-value determined by one-way ANOVA with Tukey Test for multiple comparisons. ns: not significant ($p \geq 0.05$), *: $p \leq 0.05$, **: $p \leq 0.01$, ***: $p \leq 0.001$.

Supplemental Table 3. Time point comparison for percent of proliferating fibroblasts after isoproterenol treatment.

| | | Days of isoproterenol injection | | | | |
|---------------------------------|----|---------------------------------|----|----|-----|----|
| | | Saline | 2 | 4 | 7 | 10 |
| Days of isoproterenol injection | 2 | ns | | | | |
| | 4 | ns | ns | | | |
| | 7 | ** | * | ns | | |
| | 10 | ns | ns | ns | ** | |
| | 14 | ns | ns | ns | *** | ns |

P-value determined by one-way ANOVA with Tukey Test for multiple comparisons. ns: not significant ($p \geq 0.05$), *: $p \leq 0.05$, **: $p \leq 0.01$, ***: $p \leq 0.001$.

Supplemental Table 4. Time point comparison for percent of proliferating fibroblasts after myocardial infarction.

| | | Days after myocardial infarction | | | | | | | |
|----------------------------------|----|----------------------------------|-----|-----|-----|-----|-----|-----|----|
| | | Sham | 1 | 2 | 3 | 4 | 5 | 7 | 9 |
| Days after myocardial infarction | 1 | ns | | | | | | | |
| | 2 | ns | ns | | | | | | |
| | 3 | ** | ** | ns | | | | | |
| | 4 | *** | *** | *** | ns | | | | |
| | 5 | *** | *** | *** | * | ns | | | |
| | 7 | ** | ** | ns | ns | * | ** | | |
| | 9 | ns | ns | ns | * | *** | *** | ** | |
| | 21 | ns | ns | ns | *** | *** | *** | *** | ns |

P-value determined by one-way ANOVA with Tukey Test for multiple comparisons. ns: not significant ($p \geq 0.05$), *: $p \leq 0.05$, **: $p \leq 0.01$, ***: $p \leq 0.001$.